A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501535-16-00

Acronym

20210263

Enrollment

Registered

2023-03-21

Start date

Unknown

Completion date

Unknown

Last updated

2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis (AD)

Brief summary

Treatment-emergent serious adverse events

Interventions

None listed

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Treatment-emergent serious adverse events	—

Countries

Austria, Denmark, Finland, Germany, Hungary, Italy, Poland, Portugal, Spain

Outcome results